Elnekave Eldad, Atar Eli, Amar Shirah, Bruckheimer Elchanan, Knizhnik Michael, Yaniv Isaac, Dujovny Tal, Feinmesser Meora, Ash Shifra
Department of Diagnostic Radiology, Rabin Medical Center, Beilinson Hospital, Petach Tikva 4941492, Israel; Institute of Oncology, Davidoff Center, Rabin Medical Center, Beilinson Hospital, Petach Tikva 4941492, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Department of Diagnostic Radiology, Rabin Medical Center, Beilinson Hospital, Petach Tikva 4941492, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
J Vasc Interv Radiol. 2018 Oct;29(10):1376-1382. doi: 10.1016/j.jvir.2018.04.009. Epub 2018 Jul 31.
Systemic doxorubicin is effective for desmoid fibromatosis (DF), but its use is limited by dose-dependent cardiotoxicity. A protocol of selective intra-arterial doxorubicin drug-eluting embolization (DEE) was designed to maximize target tissue efficacy of doxorubicin, while minimizing systemic exposure. Four children with recurrent or refractory DF were treated between 2014 and 2017. Tumor volumes were reduced by 54%-97% over a follow-up interval of 6-32 months. A single patient experienced transient lower extremity paresthesia (Common Terminology Criteria for Adverse Events grade I). Further investigation is needed to better establish these promising results for doxorubicin DEE in DF treatment.
全身使用阿霉素对硬纤维瘤（DF）有效，但其应用受剂量依赖性心脏毒性的限制。设计了一种选择性动脉内阿霉素药物洗脱栓塞术（DEE）方案，以最大限度地提高阿霉素对靶组织的疗效，同时尽量减少全身暴露。2014年至2017年期间，对4例复发性或难治性DF患儿进行了治疗。在6至32个月的随访期内，肿瘤体积缩小了54%至97%。1例患者出现短暂性下肢感觉异常（不良事件通用术语标准I级）。需要进一步研究，以便更好地确立阿霉素DEE在DF治疗中这些有前景的结果。
